TAPI1

Research use only, not for human use.

TAPI-1, an ADAM17/TACE inhibitor, inhibits shedding of cytokine receptors.

TAPI-1, an ADAM17/TACE inhibitor, inhibits shedding of cytokine receptors.(In Vitro):TAPI-1 prevents unstimulated and PMA-induced release of the soluble forms of TNF-alpha, p60 TNFR, and IL-6R from the monocytic cell line, THP-1, and from human peripheral blood monocytes. TAPI also inhibits LPS-induced shedding of the p60 TNFR and TNF-alpha from monocytes. TAPI-1 inhibits TACE-dependent constitutive release of co-transfected APP(695). TAPI-1 attenuates Ang II-induced EGFR transactivation and cell proliferation in human HSC line LI90. TAPI-1 with the EGFR inhibitor AG1478 exhibits deactivated AREG/EGFR/ERK signaling pathway and reduces pro-inflammatory cytokines release in pSS salivary gland-derived epithelial cells.

Cell Viability Assay Cell Line:LPS-treated HK-2 cells Concentration:1 μM Incubation Time:30 minutes (pre-treated)Result:Increased cell viability.

——

TAPI 1 | TAPI-1 | TAPI

Metabolic Enzyme/Protease

MMP

——

——

——

163847-77-6

499.612

C26H37N5O5

>98% (HPLC)

In Vitro:?DMSO : ≥ 31 mg/mL (62.05 mM)

CC(C)CC(CC(=O)NO)C(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)NCCN

——

(-20℃)

With Ice Pack

≥ 2 years